| 2.24 -0.14 (-5.88%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.02 | 1-year : | 3.53 |
| Resists | First : | 2.58 | Second : | 3.02 |
| Pivot price | 2.32 |
|||
| Supports | First : | 1.74 | Second : | 1.22 |
| MAs | MA(5) : | 2.38 |
MA(20) : | 2.27  |
| MA(100) : | 1.57 |
MA(250) : | 1.67 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 46 |
D(3) : | 60.4 |
| RSI | RSI(14): 55.5 |
|||
| 52-week | High : | 2.89 | Low : | 1.12 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LUNG ] has closed above bottom band by 27.2%. Bollinger Bands are 24% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.4 - 2.42 | 2.42 - 2.43 |
| Low: | 2.2 - 2.21 | 2.21 - 2.23 |
| Close: | 2.21 - 2.24 | 2.24 - 2.26 |
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
Wed, 02 Sep 2026
LUNG stock reacts to Pulmonx inducement grants for new hires - AD HOC NEWS
Tue, 01 Sep 2026
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Technology Magazine
Thu, 27 Aug 2026
Pulmonx to Participate in Upcoming Investor Conferences - The Manila Times
Wed, 26 Aug 2026
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance
Fri, 14 Aug 2026
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Thu, 13 Aug 2026
Morgan Stanley (LUNG) reports 6.9% Pulmonx stake in updated ownership filing - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 43 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 62.8 (%) |
| Shares Short | 1,060 (K) |
| Shares Short P.Month | 1,150 (K) |
| EPS | -1.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.91 |
| Profit Margin | -55.1 % |
| Operating Margin | -39.8 % |
| Return on Assets (ttm) | -22.2 % |
| Return on Equity (ttm) | -88.9 % |
| Qtrly Rev. Growth | -4.6 % |
| Gross Profit (p.s.) | 1.56 |
| Sales Per Share | 2.03 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -1.95 |
| PEG Ratio | 0 |
| Price to Book value | 2.46 |
| Price to Sales | 1.1 |
| Price to Cash Flow | -3.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|